In hematological malignancies such as ALL, aberrant STAT3 activation often coincides with p53 pathway attenuation, and a recent study demonstrated that pharmacological or genetic STAT3 inhibition leads to induction of the p53 response in B-ALL cells [86], demonstrating the therapeutic potential of targeting this axis. This evidence concerns the gene STAT3 and acute lymphoblastic leukemia.